Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982592 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT00982592 is a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 124 participants, above the 75-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00982592, a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies combination chemotherapy when given together with vismodegib to see how well it works compared with combination chemotherapy without vismodegib in treating patients with advanced stomach cancer or gastroesophageal junction cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Vismodegib may stop the growth of stomach or gastroesophageal junction cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether combination chemotherapy is more effective when given with or without vismodegib in treating stomach cancer and gastroesophageal junction cancer.
Conditions Studied
Interventions
- OTHER placebo
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG vismodegib
Study Locations (20)
Illinois
- University of Chicago - Chicago
- Cancer Care Center of Decatur - Decatur
- Decatur Memorial Hospital - Decatur
- Crossroads Cancer Center - Effingham
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Ingalls Memorial Hospital - Harvey
- Loyola University Medical Center - Maywood
- Illinois CancerCare-Peoria - Peoria
- Illinois Oncology Research Association CCOP - Peoria
- Memorial Medical Center - Springfield
New York
- Beth Israel Medical Center - New York
- New York University Langone Medical Center - New York
- Saint Luke's Roosevelt Hospital Center - Saint Luke's Division - New York
- Columbia University Medical Center - New York
Indiana
- Fort Wayne Medical Oncology and Hematology Inc-Parkview - Fort Wayne
- Indiana University Medical Center - Indianapolis
Michigan
- University of Michigan University Hospital - Ann Arbor
- University of Michigan - Ann Arbor
California
- University of California at Davis Cancer Center - Sacramento
Missouri
- Saint John's Mercy Medical Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982592
The ClinicalTrials.gov registry entry for NCT00982592 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 75-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (65% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Adenocarcinoma of the Gastroesophageal Junction appearing as the primary indexed condition, and to 5 interventions - of which placebo is the first listed.
NCT00982592 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Illinois, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT00982592 about?
NCT00982592 is a clinical study titled "Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer". This randomized phase II trial studies combination chemotherapy when given together with vismodegib to see how well it works compared with combination chemotherapy without vismodegib in treating patients with advanced stomach cancer or gastroesophageal junction cancer. Drugs used in chemotherapy, su...
What is the current status of trial NCT00982592?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2009-09. Estimated completion is 2014-10.
What conditions does trial NCT00982592 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Gastroesophageal Junction, Stage IV Gastric Cancer, Recurrent Gastric Cancer, Stage IIIB Gastric Cancer, Adenocarcinoma of the Stomach.
What interventions are being tested in trial NCT00982592?
The interventions under investigation include: placebo (OTHER), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), vismodegib (DRUG).
Who is sponsoring clinical trial NCT00982592?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00982592 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Gastroesophageal Junction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Induction FLOT With CROSS CRT for Esophageal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
COMPLETED · Phase 2
-
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
COMPLETED · Phase 2
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
Explore more on PlainTrial
Adenocarcinoma of the Gastroesophageal Junction
All registered trials for this condition
Stage IV Gastric Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.